Circulating stem cells (CTCs), Minetta Liu told reporters at the 2010 San Antonio Breast Cancer Symposium, are "a hot topic. But . . . we actually don't know what they are." Read More
Molecular Insight Pharmaceuticals Inc. will undergo a corporate reorganization under a Chapter 11 filing pursuant to a $45 million financing commitment from Savitr Capital LLC. Read More
EpiCept Corp. stock (NASDAQ:EPCT) climbed 38.6 percent, gaining 27 cents, to close at 97 cents Friday, following word from the Tarrytown, N.Y.-based company that a new analysis supported the favorable impact of Ceplene (histamine dihydrochloride) on overall survival and its activity with interleukin-2 (IL-2) in patients with acute myeloid leukemia (AML). Read More
• MorphoSys AG, of Martinsried, Germany, said its subsidiary, Sloning BioTechnology GmbH, signed a nonexclusive license and technology transfer deal with Pfizer Inc., of New York, covering the installation, training and use of Sloning's Slonomics platform for fabrication of highly diverse gene and protein libraries and Pfizer's subsidiary, Rinat NeuroScience Corp. Read More
• Arena Pharmaceuticals Inc., of San Diego, started dosing in a Phase I trial of APD811, an oral candidate designed to target the prostacyclin receptor for treatment of pulmonary arterial hypertension. The study is expected to enroll up to 72 healthy adult volunteers to test single-ascending doses of the drug. Read More
Scientists from Vanderbilt University described why the 2009 pandemic H1N1 flu strain, as well as other pandemic strains, appeared to cause disproportionate damage in middle-aged individuals. While seasonal flu strains tend to pick off the very old, the very young and the immunocompromised, pandemic flu strains are often most deadly to the people best able to fend off other types of infectious diseases: healthy adults. Read More
Anaphore Inc. is expected to announce Monday morning that it has snagged its first big pharma partnership for its Atrimer protein engineering platform, a deal with Mitsubishi Tanabe Pharma Corp. that could be worth up to $345 million. Read More
WASHINGTON – A district judge's interpretation of the Dickey-Wicker Amendment was "fundamentally flawed" when the court ruled that human embryonic stem cell (hESC) research was illegal, and therefore, the order should be reversed, a government lawyer argued last week before a three-judge panel from the U.S. Circuit Court of Appeals for the District of Columbia. Read More
